Literature DB >> 17503249

Rattlesnake envenomation with neurotoxicity refractory to treatment with crotaline Fab antivenom.

William H Richardson1, Collin S Goto, David J Gutglass, Saralyn R Williams, Richard F Clark.   

Abstract

INTRODUCTION: Neurotoxicity following rattlesnake envenomation is reported with certain crotaline species. In some instances, crotaline Fab antivenom therapy that effectively halts progression of local tissue edema and hemotoxicity fails to reverse neurologic venom effects. CASE SERIES: A 50-year-old man presented following a rattlesnake envenomation to the left ring finger. He had swelling and pain in the affected hand and complained of dyspnea and dysphonia. Significant fasciculations were seen in the face, tongue, neck, trunk, and arms. The patient received crotaline Fab antivenom but continued to develop worsening respiratory distress. His respiratory insufficiency requiring ventilatory support appeared related to respiratory muscle incoordination as extremity motor function remained intact. Initial control of local edema progression and hematologic parameters was achieved with antivenom, but diffuse fasciculations involving the entire body worsened despite aggressive antivenom treatment. In another case, a 9-year-old boy was envenomated by a rattlesnake on the left thenar eminence. He presented with pain and swelling up to the forearm and fasciculations of the tongue, face, and upper extremities. The progression of edema was halted at the mid-bicep level and hematologic parameters normalized with crotaline Fab antivenom. However, fasciculations continued for two days despite antivenom treatment.
CONCLUSION: We describe two cases of neurotoxicity following rattlesnake envenomation in which treatment with crotaline Fab antivenom adequately obtained initial control of local swelling and hematologic effects, but neurotoxic venom effects remained refractory to antivenom therapy. This phenomenon is anecdotally recognized following certain crotaline species envenomations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17503249     DOI: 10.1080/15563650701338187

Source DB:  PubMed          Journal:  Clin Toxicol (Phila)        ISSN: 1556-3650            Impact factor:   4.467


  7 in total

1.  A case of neurotoxicity following envenomation by the Sidewinder rattlesnake, Crotalus cerastes.

Authors:  Adam R Bosak; Anne-Michelle Ruha; Kimberlie A Graeme
Journal:  J Med Toxicol       Date:  2014-06

2.  Unified treatment algorithm for the management of crotaline snakebite in the United States: results of an evidence-informed consensus workshop.

Authors:  Eric J Lavonas; Anne-Michelle Ruha; William Banner; Vikhyat Bebarta; Jeffrey N Bernstein; Sean P Bush; William P Kerns; William H Richardson; Steven A Seifert; David A Tanen; Steve C Curry; Richard C Dart
Journal:  BMC Emerg Med       Date:  2011-02-03

Review 3.  Crotaline Fab antivenom appears to be effective in cases of severe North American pit viper envenomation: an integrative review.

Authors:  Eric J Lavonas; Tammi H Schaeffer; Jamie Kokko; Sara L Mlynarchek; Gregory M Bogdan
Journal:  BMC Emerg Med       Date:  2009-06-22

Review 4.  Neurotoxicity in snakebite--the limits of our knowledge.

Authors:  Udaya K Ranawaka; David G Lalloo; H Janaka de Silva
Journal:  PLoS Negl Trop Dis       Date:  2013-10-10

Review 5.  Snakebite management in Iran: Devising a protocol.

Authors:  Seyed Mostafa Monzavi; Bita Dadpour; Reza Afshari
Journal:  J Res Med Sci       Date:  2014-02       Impact factor: 1.852

6.  Neuromuscular Effects of Common Krait (Bungarus caeruleus) Envenoming in Sri Lanka.

Authors:  Anjana Silva; Kalana Maduwage; Michael Sedgwick; Senaka Pilapitiya; Prasanna Weerawansa; Niroshana J Dahanayaka; Nicholas A Buckley; Christopher Johnston; Sisira Siribaddana; Geoffrey K Isbister
Journal:  PLoS Negl Trop Dis       Date:  2016-02-01

Review 7.  Amplification of Snake Venom Toxicity by Endogenous Signaling Pathways.

Authors:  Philip E Bickler
Journal:  Toxins (Basel)       Date:  2020-01-22       Impact factor: 4.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.